Vaccine company, Valneva, announced this week that its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ®, showed a sustained 98.3% sero-response rate one-year after single vaccination in adolescents (12 to 17 years old) in Phase 3 trials.
Share this post
Chikungunya vaccine shows sustained high…
Share this post
Vaccine company, Valneva, announced this week that its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ®, showed a sustained 98.3% sero-response rate one-year after single vaccination in adolescents (12 to 17 years old) in Phase 3 trials.